New targeted drug shows promise for tough ovarian cancer
Disease control
Ongoing
This phase 2 trial tests a drug called CYH33 in 93 women with recurrent ovarian, fallopian tube, or peritoneal clear cell carcinoma that has a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer grow. The main goal is to see if it shr…
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC